Penwest Pharmaceuticals Co., a drug development company, focuses on identifying and developing products that address unmet medical needs, primarily for disorders of the nervous system. Its proprietary drug delivery technologies include TIMERx, a controlled-release technology; Geminex, a technology enabling drug release at two different rates; SyncroDose, a technology enabling controlled release at the appropriate site in the body; and GastroDose system, a technology enabling drug delivery to the upper gastrointestinal tract. The company offers Opana ER, an oral extended release opioid analgesic for patients with moderate to severe pain requiring continuous opioid treatment using its TIMERx drug delivery technology; and Nifedipine XL, a generic version of Procardia XL, which is used for the treatment of hypertension and angina based on its TIMERx technology. Its products under development include Nalbuphine ER, a Phase IIa clinical trail completed product for the treatment of pain; and A0001, a Phase IIa clinical trail product for the treatment of diseases related to the inherited mitochondrial respiratory chain diseases. Penwest Pharmaceuticals Co. has strategic, collaborative, drug development, and licensing agreements with various companies, including Endo Pharmaceuticals Inc.; Edison Pharmaceuticals, Inc.; Mylan Pharmaceuticals Inc.; Otsuka Pharmaceuticals Co.; and Alvogen, Inc. The company was founded in 1991 and is based Patterson, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for PPCO